Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Brain : a journal of neurology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/brain/awq056PMID 20360050PMCID PMC2859150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review.

  2010cited by this paper
• Amyloid Reduction by Amyloid-β Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

  2009cited by this paper
• Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease.

  2009influential reference
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008influential reference
• Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

  2008cited by this paper
• Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease

  2008cited by this paper
• Consequence of A b immunization on the vasculature of human Alzheimer’s disease brain

  2008cited by this paper
• Blocking Aβ42 Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between Aβ and Tau Pathology

  2008cited by this paper
• Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

  2007cited by this paper
• Mitochondrial degeneration in dystrophic neurites of senile plaques may lead to extracellular deposition of fine filaments

  2007cited by this paper
• Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

  2007cited by this paper
• Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice

  2007cited by this paper
• Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis

  2006cited by this paper
• β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

  2005cited by this paper
• Molecular recycling within amyloid fibrils

  2005cited by this paper
• Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.

  2005cited by this paper
• Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

  2005cited by this paper
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

  2005influential reference
• Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

  2005cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies

  2005cited by this paper
• Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques.

  2004cited by this paper
• Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid-β Plaques

  2004cited by this paper
• Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

  2004cited by this paper
• Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

  2004influential reference
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease

  2004cited by this paper
• Pubertal Changes in Biochemical Markers of Growth

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Slow Cognitive Decline in Alzheimer’s Disease

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• In Vivo Multiphoton Imaging of a Transgenic Mouse Model of Alzheimer Disease Reveals Marked Thioflavine‐S‐Associated Alterations in Neurite Trajectories

  2003cited by this paper
• Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

  2003cited by this paper
• Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

  2003cited by this paper
• Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations

  2003influential reference
• Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease

  2002cited by this paper
• A b peptide vaccination prevents memory loss in an animal model of Alzheimer ' s disease

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

  2000cited by this paper
• Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

  2000cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease.

  1999influential reference
• Diffuse, Lake-like Amyloid-β Deposits in the Parvopyramidal Layer of the Presubiculum in Alzheimer Disease

  1998cited by this paper
• Stereology: A Practical Primer for Neuropathology

  1998cited by this paper
• Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease

  1997cited by this paper
• Aggregation and disaggregation of senile plaques in Alzheimer disease.

  1997cited by this paper
• Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease

  1996cited by this paper
• The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology*

  1996cited by this paper
• Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404

  1994cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

  1990cited by this paper
• The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes.

  1989cited by this paper
• ALZHEIMER'S DISEASE--AN ELECTRON MICROSCOPICAL STUDY.

  1964cited by this paper

• Vaccine research in cognitive impairment and dementia: a bibliometric analysis and future outlook (2000–2025)

  2025cites this paper
• Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.

  2025cites this paper
• Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease

  2024cites this paper
• The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

  2024cites this paper
• Amyloid removal and the appearance of brain volume loss.

  2024cites this paper
• Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.

  2024cites this paper
• The advent of Alzheimer treatments will change the trajectory of human aging

  2024influential citation
• Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer’s Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study

  2023cites this paper
• Natural IgG antibodies to β amyloid are decreased in patients with Parkinson’s disease

  2023cites this paper
• Aβ1-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson’s disease

  2023cites this paper
• Effect and Potential Mechanism of Immunotherapy on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Association of mTOR Pathway and Conformational Alterations in C-Reactive Protein in Neurodegenerative Diseases and Infections

  2023cites this paper
• The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators.

  2022cites this paper
• Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease

  2022cites this paper
• Hope or hype? Aducanumab as a magic bullet for Alzheimer’s disease

  2022cites this paper
• Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability

  2022cites this paper
• Caffeine Restores Neuronal Damage and Inflammatory Response in a Model of Intraventricular Hemorrhage of the Preterm Newborn

  2022cites this paper
• Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease.

  2022cites this paper
• Combination therapy for the treatment of alzheimer's disease: recent progress and future prospects.

  2022cites this paper
• Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease.

  2021cites this paper
• Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives

  2021cites this paper
• Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes.

  2021cites this paper
• Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease

  2020cites this paper
• The role of the microbiota-gut-brain axis in neuropsychiatric disorders

  2020cites this paper
• Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials

  2020cites this paper
• Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model

  2020cites this paper
• Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

  2020cites this paper
• Combination Drug Therapy for the Management of Alzheimer’s Disease

  2020cites this paper
• Persistent neuropathological effects 14 years following amyloid- b immunization in Alzheimer’s disease

  2019cites this paper
• Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old

  2019cites this paper
• Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

  2019cites this paper
• Ethical issues in early diagnosis and prevention of Alzheimer disease

  2019cites this paper
• Could changing the course of Alzheimer's disease pathology with immunotherapy prevent dementia?

  2019cites this paper
• Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.

  2019cites this paper
• Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline

  2019cites this paper
• Modern approaches to investigating non‐neuronal aspects of Alzheimer's disease

  2019cites this paper
• Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies.

  2019cites this paper
• Application of anti-amyloid beta immunization using encapsulated cell technology in mouse models of Alzheimer's disease

  2019cites this paper
• Progress in Target Drug Molecules for Alzheimer's Disease.

  2019cites this paper
• Phos‐tau peptide immunization of amyloid‐tg‐mice reduced non‐mutant phos‐tau pathology, improved cognition and reduced amyloid plaques

  2018cites this paper
• Inhibitory effects of Mas-related gene (Mrg) C receptor on chronic morphine-induced spinal glial activation in rats

  2018cites this paper
• Microglial phagocytosis of amyloid plaques in an ex vivo model of Alzheimer's Disease

  2018cites this paper
• Downregulated apoptosis and autophagy after anti‐Aβ immunotherapy in Alzheimer's disease

  2018cites this paper
• Tau-targeting therapies for Alzheimer disease

  2018cites this paper
• Detection of cortical changes in Alzheimer’s disease patients at ultra-high field MRI

  2018cites this paper
• Tau Proteins and Tauopathies in Alzheimer’s Disease

  2018cites this paper
• Inhibitory Effects of Mas-Related Gene C Receptor on Chronic Morphine-Induced Spinal Glial Activation in Rats

  2018cites this paper
• Sisyphus in Neverland

  2017cites this paper
• Exploration of Various Proteins for the Treatment of Alzheimer's Disease.

  2017cites this paper
• Antibody Therapeutics Targeting Aβ and Tau.

  2017cites this paper
• Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

  2017cites this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cites this paper
• Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases

  2016influential citation
• Mechanisms of amyloid-beta cytotoxicity in hippocampal network function : rescue strategies in Alzheimer's disease

  2016cites this paper
• Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.

  2016cites this paper
• Investigating imaging biomarkers of neuroinflammation and neurodegeneration in rodent models of Alzheimer's disease

  2016cites this paper
• Active Immunization Against the Amyloid-β Peptide

  2016cites this paper
• A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.

  2016cites this paper
• Recent Perspective About the Amyloid Cascade Hypothesis and Stem Cell-Based Therapy in the Treatment of Alzheimer's Disease

  2016cites this paper
• Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors

  2016cites this paper
• A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration

  2016cites this paper
• Active Vaccines for Alzheimer Disease Treatment.

  2016cites this paper
• Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.

  2016cites this paper
• Young microglia restore amyloid plaque clearance of aged microglia

  2016cites this paper
• Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

  2015cites this paper
• Current thinking on the mechanistic basis of Alzheimer's and implications for drug development

  2015cites this paper
• The case for rejecting the amyloid cascade hypothesis

  2015cites this paper
• Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.

  2015cites this paper
• Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

  2015cites this paper
• Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

  2015cites this paper
• Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

  2015cites this paper
• Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance

  2015cites this paper
• Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

  2015cites this paper
• Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease

  2015influential citation
• Forschung mit Menschen, die an Demenz erkrankt sind?

  2015cites this paper
• Research with dementia patients

  2015cites this paper
• Forschung mit Menschen, die an Demenz erkrankt sind?

  2015cites this paper
• [Research on humans suffering from dementia].

  2015cites this paper
• The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

  2014cites this paper
• p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.

  2014cites this paper
• Perspective The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

  2014cites this paper
• Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D

  2014cites this paper
• The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

  2014cites this paper
• Serotonergic Signaling Pathways that Suppress Amyloid Beta in Mouse Models of AD

  2014cites this paper
• Immunotherapy for Alzheimer’s disease: past, present and future

  2014cites this paper
• A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease

  2014cites this paper
• Alum and Squalene-Oil-in-Water Emulsion Enhance the Titer and Avidity of Anti-Aβ Antibodies Induced by Multimeric Protein Antigen (1–11)E2, Preserving the Igg1-Skewed Isotype Distribution

  2014cites this paper
• The "memory kinases": roles of PKC isoforms in signal processing and memory formation.

  2014cites this paper
• Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy

  2014cites this paper
• Harnessing the Immune System for Treatment and Detection of Tau Pathology

  2014cites this paper
• Predicting Cognitive Decline in Older Adults Through Multi-Voxel Pattern Analysis

  2014cites this paper
• Detection of cortical changes in Alzheimer’s disease at ultra-high field MRI Chapter

  2014cites this paper
• Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures.

  2014cites this paper
• Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer's Disease

  2013cites this paper
• Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease.

  2013cites this paper
• Investigating Interventions in Alzheimer's Disease with Computer Simulation Models

  2013cites this paper
• Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

  2013cites this paper
• Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

  2013cites this paper
• Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy

  2013cites this paper
• Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of Aβ Species and Amyloidogenic Peptides

  2013cites this paper